Localization and quantification of mRNA for matrix metalloproteinase‐2 (MMP‐2) and tissue inhibitor of matrix metalloproteinase‐2 (TIMP‐2) in human benign and malignant prostatic tissue

The family of matrix metalloproteinases (MMPs) has been shown to be involved in proteolytic degradation of the extracellular matrix, which is an essential step in tumor invasion and metastasis. MMPs are tightly regulated by the levels of active enzymes and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). MMP‐2 and its ratio to TIMP‐2 have been associated with tumor recurrence and progression in a number of human malignancies.

[1]  S. Kitazawa,et al.  Serum matrix metalloproteinase‐2 and its density in men with prostate cancer as a new predictor of disease extension , 1998, International journal of cancer.

[2]  S. Loening,et al.  Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: Analytical aspects , 1998, The Prostate.

[3]  M. Nakajima,et al.  Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. , 1998, British Journal of Cancer.

[4]  F. Hamdy,et al.  Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. , 1997, Cancer research.

[5]  M. Wilson,et al.  Human prostate tumor angiogenesis in nude mice: Metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells , 1997, The Anatomical record.

[6]  P. Wingo,et al.  An adjustment to the 1997 estimate for new prostate cancer cases , 1997, CA: a cancer journal for clinicians.

[7]  J. Greene,et al.  Molecular Cloning and Characterization of Human Tissue Inhibitor of Metalloproteinase 4* , 1996, The Journal of Biological Chemistry.

[8]  M. Kattan,et al.  Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index , 1996, Cancer.

[9]  M. Nakajima,et al.  Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. , 1996, Cancer research.

[10]  D. Grignon,et al.  High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. , 1996, Cancer research.

[11]  H. Friess,et al.  Expression and in‐situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer , 1995, International journal of cancer.

[12]  L. Cornelius,et al.  Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. , 1995, The Journal of investigative dermatology.

[13]  R. Hembry,et al.  The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. , 1995, Surgical oncology.

[14]  F. Sarkar,et al.  Enhanced expression of tissue inhibitor of metalloproteinase‐2 (TIMP‐2) in the stroma of breast carcinomas correlates with tumor recurrence , 1994, International journal of cancer.

[15]  G. Stamp,et al.  Expression and activity of MMPS and their regulators in ovarian cancer , 1994, International journal of cancer.

[16]  Y. Soini,et al.  72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  A. Boag,et al.  Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. , 1994, The American journal of pathology.

[18]  A. Hanby,et al.  Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. , 1993, Cancer research.

[19]  C. Clavel,et al.  Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas. , 1993, Pathology, research and practice.

[20]  G. Stamp,et al.  Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. , 1993, Journal of clinical pathology.

[21]  M. Stearns,et al.  Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. , 1993, Cancer research.

[22]  A. Eisen,et al.  Localization of 92-kDa type IV collagenase in human skin tumors: comparison with normal human fetal and adult skin. , 1993, The Journal of investigative dermatology.

[23]  R Poulsom,et al.  Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. , 1992, The American journal of pathology.

[24]  T. Hurskainen,et al.  Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. , 1992, Cancer research.

[25]  J. Woessner,et al.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[27]  A. Eisen,et al.  Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Brawer,et al.  The relationship of basement membrane to histologic grade of human prostatic carcinoma. , 1989, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[29]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[30]  Y. Soini,et al.  Expression of the tissue metalloproteinase inhibitors TIMP-1 and TIMP-2 in malignant fibrous histiocytomas and dermatofibromas as studied by in situ hybridization and immunohistochemistry. , 1996, Human pathology.

[31]  M. Stearns,et al.  Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. , 1996, Invasion & metastasis.

[32]  M. Stearns,et al.  Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a)expression in human prostate cancer. , 1996, Oncology research.

[33]  T. Cawston.  Metalloproteinase inhibitors and the prevention of connective tissue breakdown. , 1996, Pharmacology & therapeutics.

[34]  J. Estève,et al.  Cancer in the European Community and its member states. , 1990, European journal of cancer.

[35]  L. Liotta,et al.  Biochemical interactions of tumor cells with the basement membrane. , 1986, Annual review of biochemistry.